| VIB VZW Patent applications |
| Patent application number | Title | Published |
|---|
| 20120136045 | SCREENING FOR COMPOUNDS THAT MODULATE GPR3-MEDIATED BETA-ARRESTIN SIGNALING AND AMYLOID BETA PEPTIDE GENERATION - The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to the screening of compounds that modulate GPR3 activity and/or beta-arrestin signaling in a mammalian cell and, in particular, compounds that reduce the formation of amyloid beta peptides. The invention also relates to inhibiting agents targeting beta-arrestin signaling and pharmaceutical compositions thereof, and their use in therapeutic applications of those disorders. | 05-31-2012 |
| 20120094864 | EXTRACELLULAR ALLOSTERIC INHIBITOR BINDING DOMAIN FROM A TYROSINE KINASE RECEPTOR - The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor. | 04-19-2012 |
| 20120029174 | METHODS FOR PRODUCING SUBSTANTIALLY HOMOGENEOUS HYBRID OR COMPLEX N-GLYCANS IN METHYLOTROPHIC YEASTS - The present invention provides methods for effectively and efficiently converting methylotrophic yeast's heterogeneous high mannose-type N-glycosylation to mammalian-type N-glycosylation by disruption of an endogenous glycosyltransferase gene (OCH1) and step-wise introduction of heterologous glycosidase and glycosyltransferase activities. Each engineering step includes a number of stages: transformation with an appropriate vector, cultivation of a number of transformants, performance of sugar analysis and heterologous protein expression analysis, and selection of a desirable clone. The selected clone is then subjected to the next engineering step. | 02-02-2012 |
| 20120023624 | MEANS AND METHODS FOR MEDIATING PROTEIN INTERFERENCE - The present invention belongs to the field of functional proteomics and more particularly to the field of protein aggregation. The invention discloses a method for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and which induces aggregation upon contact with said target protein. The present invention also discloses such interferor molecules and their use in agrobiotech applications. | 01-26-2012 |
| 20120022135 | PHD2 INHIBITION FOR BLOOD VESSEL NORMALIZATION, AND USES THEREOF - A key function of blood vessels, to supply oxygen, is impaired in tumors because of abnormalities in their endothelial lining. PHD proteins serve as oxygen sensors and may regulate oxygen delivery. Therefore the role of endothelial PHD2 in vessel shaping by implanting tumors in PHD2 | 01-26-2012 |
| 20120005774 | USE OF TREHALASE TO OBTAIN DROUGHT RESISTANCE IN PLANTS - The present invention relates to the use of trehalase to obtain drought and/or salt resistance in plants. More specifically, it relates to genetically modified constructs, transformed into plants and resulting in overexpression of trehalase, whereby the transformed plants show a significantly better drought resistance during the drought period, and a better recovery when water is supplied after the drought period. | 01-05-2012 |
| 20110262348 | Selective targeting of intratumoral cells - The present invention relates to the field of tumor growth and biology. The invention relates to activities and characteristics of tumor-associated macrophages, and uses of such for the diagnosis and treatment of cancer and tumor growth. | 10-27-2011 |
| 20110250209 | INHIBITION OF PLGF TO TREAT PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIA - The present application relates to the field of leukemias, and more in particular to how P1 GF inhibition can help to treat Philadelphia chromosome positive (Ph+) leukemias. Methods are provided for treating Ph+ leukemias by administering P1 GF inhibitors. Also disclosed are uses of P1 GF inhibitors in the treatment of Ph+ leukemias, or for the preparation of a medicament against Ph+ leukemias. | 10-13-2011 |
| 20110244011 | SPECIFIC DELIVERY OF AGROCHEMICALS - The present invention relates to specific delivery of agrochemicals to plants. More specifically, it relates to a composition, essentially consisting of a targeting agent comprising at least one binding domain that specifically binds to a binding site on an intact living plant and an agrochemical or a combination of agrochemicals. The present invention relates further to a binding domain that specifically binds the binding site on an intact living plant. More specifically, it relates to binding domains comprising an amino acid sequence that comprises four framework regions and three complementary determining regions, or any suitable fragment thereof, whereby the binding domains are capable to bind or retain a carrier onto a plant. In one preferred embodiment, the invention relates to binding domains which specifically bind trichomes, stomata, cuticle, lenticels, thorns, spines, root hairs, or wax layer. The invention relates further to a method for delivery of agrochemicals to a plant, for improving the deposition of agrochemicals on a plant, and for retaining the agrochemicals on a plant, using targeting agents comprising the binding domains, and to a method for protecting a plant against biotic or abiotic stress or controlling plant growth using the same. Also, the invention relates to a method for manufacturing a specifically targeting agrochemical carrier. | 10-06-2011 |
| 20110191913 | CELLS PRODUCING GLYCOPROTEINS HAVING ALTERED GLYCOSYLATION PATTERNS AND METHOD AND USE THEREOF - The present application relates to the field of glyco-engineering, more specifically to eukaryotic cells wherein both an endoglucosaminidase and a glycoprotein are present. These cells can be used to deglycosylate or partly deglycosylate the (exogenous) glycoprotein, in particular without the need for adding an extra enzyme. Methods are also provided for the application of these cells in protein production. According to one specific aspect, the eukaryotic cells and methods are glyco-engineered yeast cells in which additionally at least one exogenous enzyme needed for complex glycosylation is present, e.g. allowing easier separation of differentially glycosylated glycoproteins. | 08-04-2011 |
| 20110184049 | LIVER-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOF - The present invention relates to nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy. | 07-28-2011 |
| 20110162109 | Plants Having Modified Growth Characteristics and a Method for Making the Same - The present invention relates generally to the field of molecular biology and concerns a method for improving various economically important growth characteristics in plants. More specifically, the present invention concerns inter alia a method for modifying growth characteristics in plants by modulating expression in a plant of a nucleic acid encoding a HUB1 (Histone Monoubiquitination 1) polypeptide or encoding another protein useful in the methods of the present invention. The modified growth characteristics comprise a modification of light regulated phenotypes, such as modified circadian clock and/or circadian clock responses, or modified plant architecture. | 06-30-2011 |
| 20110136240 | DIAGNOSTIC TEST FOR THE DETECTION OF EARLY STAGE LIVER CANCER - The invention provides methods and kits to detect early stage hepatocellular carcinoma or a change in the gradation of hepatocellular carcinoma in mammals. The diagnostic marker is based on the profiling and identification of diagnostic carbohydrates present in a body fluid such as blood serum. | 06-09-2011 |
| 20110104183 | USE OF SIP1 AS DETERMINANT OF BREAST CANCER STEMNESS - The present invention relates to the diagnosis and treatment of cancer. More specifically, it relates to the use of SIP1 nucleic acid and/or protein for the detection of breast cancer stem cells, and the repression of the gene and/or the inactivation of the protein to repress the differentiation of cells into cancer cells and to inhibit metastasis of breast cancer tumors. | 05-05-2011 |
| 20110100816 | BLOOD SERUM MARKER FOR DETECTION AND DIAGNOSIS OF ALZHEIMER'S DISEASE - The present invention relates to a blood marker for early detection and diagnosis of Alzheimer's disease. More specifically, it relates to an analysis of the protein glycan profile in the blood, and the identification of specific peak ratio's when compared to healthy aged matched subjects that are typical for Alzheimer's dementia. | 05-05-2011 |
| 20110092374 | METHODS FOR PRODUCING SUBSTANTIALLY HOMOGENEOUS HYBRID OR COMPLEX N-GLYCANS IN METHYLOTROPHIC YEASTS - The present invention provides methods for effectively and efficiently converting methylotrophic yeast's heterogeneous high mannose-type N-glycosylation to mammalian-type N-glycosylation by disruption of an endogenous glycosyltransferase gene (OCH1) and step-wise introduction of heterologous glycosidase and glycosyltransferase activities. Each engineering step includes a number of stages: transformation with an appropriate vector, cultivation of a number of transformants, performance of sugar analysis and heterologous protein expression analysis, and selection of a desirable clone. The selected clone is then subjected to the next engineering step. | 04-21-2011 |
| 20110078825 | Modulation of plant cell number - The invention relates to the use of the ANG4 gene, or a variant thereof, to modulate the cell number of a plant organ. The modulation can be used to increase the plant biomass, or to adapt the plant architecture. | 03-31-2011 |
| 20110071085 | USE OF SURVIVIN TO TREAT KIDNEY FAILURE - The present invention relates generally to methods of for the prevention and treatment for renal disease. In particular, the invention relates to methods of prevention and treatment of mammals, including humans, which are at risk of developing renal failure. This is generally in the field of treatment or prevention of acute renal failure by administration of the anti-apoptotic molecule survivin. The invention also includes the treatment of kidney transplants (renal allografts) to prolong survival of the graft during cold ischemia and immediately after transplantation. | 03-24-2011 |
| 20110065638 | NOVEL CRUSTACEAN ANDROGENIC GLAND HORMONE - The present invention relates to a novel crustacean androgenic gland hormone. More specifically, the invention relates to an androgenic gland hormone derived from | 03-17-2011 |
| 20110038887 | Novel Vaccine Against Trypanosoma Cruzi Infection - The present invention relates to a vaccine against | 02-17-2011 |
| 20110033911 | Episomal fusion gene - The present invention relates to an episomal structure expressing a functional oncogene, whereby said oncogene is a fusion gene of two chromosomal gene fragments. More specifically, the invention relates to a NUP214-ABL1 fusion product, important in the development of T-cell acute lymphoblastic leukemia, to methods to detect the fusion and to methods to prevent the oncogenic activity of said fusion product. | 02-10-2011 |
| 20110021378 | NUCLEIC ACIDS OF PICHIA PASTORIS AND USE THEREOF FOR RECOMBINANT PRODUCTION OF PROTEINS - The present invention provides the genome sequence of | 01-27-2011 |
| 20100322967 | B CELL TOLERANCE INDUCTION - The present invention relates to the induction of immune tolerance, by a novel method of induction of IL-10 production in B cells, whereby said B cells can be loaded with antigen before, during or after the induction of the IL-10 production. More specifically, the invention relates to the transduction of the B cell with a retroviral vector encoding an antigen, whereby the retroviral envelop induces IL-10 production in the B cell by activation the TLR2 receptor, in combination with its viral receptor. | 12-23-2010 |
| 20100267084 | PROTEIN GLYCOSYLATION MODIFICATION IN METHYLOTROPHIC YEAST - The present invention provides genetically engineered strains of | 10-21-2010 |
| 20100204309 | OLIGONUCLEOTIDE COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The invention relates to the identification of microRNAs whose expression is diminished in neurodegenerative disorders. In particular, the identified microRNAs can be used for the downregulation of the beta-secretase (BACE1) in mammalian brain and hence for the treatment of Alzheimer's disease. | 08-12-2010 |
| 20100152253 | NON-STEROIDAL BRASSINOSTEROID MIMETIC - The present invention relates to non-steroidal mimetics of brassinosteroids. More specifically, it relates to non-steroidal monocyclic compounds, capable of rescuing the brassinosteroid receptor null mutation bri1-116. Preferably, said compounds are low molecular weight, monocyclic halogenated compound. | 06-17-2010 |
| 20100130586 | DIAGNOSIS AND TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA - The present invention relates to the field of biotechnological means to diagnose or treat T-cell acute lymphoblastic leukaemia. More particularly, the invention relates to methods to diagnose T-cell acute lymphoblastic leukaemia via determining the presence of a duplication of the MYB gene in cells taken from patients. The invention further relates to inhibitors capable of neutralizing the biological activity of MYB alone, or in combination with inhibitors capable of neutralizing the biological activity of NOTCH1, which can be used to treat T-cell acute lymphoblastic leukaemia. | 05-27-2010 |
| 20090298066 | Sex-Specific Marker for Shrimps and Prawns - The present invention relates to a sex-specific marker for shrimps and prawns. More specifically, it relates to a sex-specific PCR-based molecular marker, derived from | 12-03-2009 |
| 20090263863 | MODIFICATION OF PROTEIN GLYCOSYLATION IN METHYLOTROPHIC YEAST - The present invention relates to methods and genetically engineered methylotrophic yeast strains for producing glycoproteins with mammalian-like glycosylation. The present invention also relates to vectors useful for generating methylotrophic yeast strains capable of producing glycoproteins with mammalian-like glycosylation. Glycoproteins produced from the genetically engineered methylotrophic yeast strains are also provided. | 10-22-2009 |
| 20090222952 | Plants Having Improved Growth Characteristics And A Method For Making The Same - The present invention concerns a method for increasing plant yield and/or increased stress resistance by decreasing the level of activity of a DEL1 polypeptide. One such method comprises introducing into a plant a nucleic acid comprising a variant DEL1 nucleic acid. Another method comprises downregulating expression of a DEL1 gene. The invention also relates to transgenic plants having introduced therein a variant DEL1 nucleic acid thereof, which plants have increased yield and/or increased stress resistance relative to control plants. The present invention also concerns a novel DEL1 protein and its encoding sequence, and constructs useful in the methods of the invention. | 09-03-2009 |
| 20090151021 | Novel Stress-Related MicroRNA Molecules and Uses Thereof - Naturally occurring and synthetic novel stress-related miRNAs are provided which can be used to modify the stress tolerance of plants. | 06-11-2009 |
| 20090047294 | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration - The invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle degeneration occurs. The invention describes transgenic mice that do not produce prolyl-hydroxylase-1, -2 or -3. It is revealed that the phenotype of the prolyl-hydroxylase 1 knock-out mouse is characterized by a protection of skeletal muscle atrophy due to a variety of muscle damages, especially ischemic insults. The invention thus relates to the use of molecules that can bind to prolyl-hydroxylase-1 for the prevention and/or treatment of skeletal muscle degeneration. | 02-19-2009 |
| 20090012275 | Means and methods for mediating protein interference - The invention belongs to the field of functional proteomics and, more particularly, to the field of protein aggregation. Described are methods for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and that induces aggregation upon contact with the target protein. The invention also discloses such interferer molecules and their use in therapeutic applications. | 01-08-2009 |
